Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

First International Summit on Interventional Pharmacoeconomics

Peter Clark, MA, MD, FRCP: A Payer Perspective

Varsha Gandhi, PhD, on Ibrutinib

Issues in Oncology

Cost of Care

The ASCO Post Staff

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Amit Sanyal, MD: A Clinician’s Perspective

Sep

Today In Oncology

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Varsha Gandhi, PhD, on Ibrutinib

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Amit Sanyal, MD: A Clinician’s Perspective

Adjuvant Alectinib Maintains Quality of Life During 2 Years of Treatment in Resected ALK-Positive NSCLC

High-Risk Prostate Cancer GETUG-AFU 18 Suggests a Role for Dose-Escalated Radiotherapy With Long-Term ADT

Extended-Interval Dosing of Tarlatamab Found Safe Effective in SCLC

Favorable Safety Profile Found for Subcutaneous Tarlatamab in ES-SCLC

Genomic Profiles Compared in Early- and Average-Onset Metastatic Colorectal Cancer